ValeantÃļt¬Õ§Q ®Æ¦A¶^1¦~
¡i©ú³ø±M°T¡j¥[®³¤j»sÃĶ°¹ÎValeant Pharmaceuticals(¹Ï)©P¤T¤½¥¬©u«×·~ÁZ¡A«ü¤½¥q¬Õ§Q¤´·|¤U¶^¤@¦~¡A¹wp¦b2019¦~«ì´_¼Wªø¡C¤½¥q¦æ¬FÁ`µô©¬©¬(Joseph Papa)±À¦æ½¨p¹º¡A¤w¦³®t¤£¦h¨â¦~¡C©¬©¬¦b¤½¥¬¤½¥q²Ä¥|©u«×¬Õ§Qªº¹q¸Ü·|ij¤W»¡¡A¥L¨ÌµM¬Û«H¡A½¨p¹º¦by¹D¤W¡A¾¨ºÞ2018¦~·|¬O§C¨¦¤@¦~¡CValeant¹wp2018¦~¦¬¤J»¹¹w´Á¡AºX¤U´X¤j¥DnÃĪ«»P«D±M§QÃĪ«ªºÄvª§§ó¤j¡C¤½¥qÁ`¦¬¤J¨üÀ£¡A¥¦¤£Â_¥X°â·~°È¡B®M²{¸êª÷¡A´î»´¤j¬ù250»õ¤¸ªº¶Å°Èt¾á¡C
Valeant¦¹«e¤w¸g¥X°âºX¤UDendreonÀù¯gÃĪ«·~°È¡A¥H¤Î¦hÓÅ@½§«~«~µP¡A´î»´¶Å°È¶W¹L20%¡C
Valeantº®u°]°È©x§ÆÛ}®¦(Paul Herendeen)®i¥Ü¤@¥÷¹Ïªí¡A¹wp2018¦~¨ì2021¦~´Á¶¡¡A¨C¦~¦³4%¨ì6%¦~§¡½Æ¦X¼Wªø²v¡C
ValeantªÑ»ù©P¤T¦b¦hÛ¦hÃÒ¨é¥æ©ö©Ò¦¬³ø21.01¥[¤¸¡A¤U¶^2.74¥[¤¸¡A¶^´T11.54%¡Q¦b¬ü°ê¯Ã¬ùÃÒ¨é¥æ©ö©Ò¤U¶^2.11¬ü¤¸¡A©Î11.41%¡A¨ì16.39¬ü¤¸¡C¥¦ªº¬üªÑ»ù´¿¦b2015¦~½Ä¨ì³»®p250¬ü¤¸¥H¤W¡A¦ý¤½¥qÃĪ«º¦»ù¡A¥Î«D¥¿²Î¤âªk¡A³z¹L¯S§OÃĩЫP¾P¡A¨üÄY®æºÊ¹î¡CValeant¤j¤Oµo®i¬Õ§Q§ó«pªº²£«~¡A¥]¬A³Õ¤hÛ(Bausch & Lomb)²´·úÅ@²z²£«~¡AG¸zÃĪ«©M¥Ö½§²£«~¡C
¥¦¹wp¦³·sÄvª§¡A¤µ¦~¦¬¤J´î¤Öªñ5»õ¤¸¡C
Valeant¹wp2018¦~¦¬¤J¦b81»õ¨ì83»õ¤¸¤§¶¡¡A´ö»¹¸ô³zªº¤ÀªRû¥§¡¹wp83.4»õ¤¸¡C
¦b12¤ë31¤éºI¤îªº²Ä¥|©u«×¡AValeant¿ý±o²b¦¬¤J5.13»õ¤¸¡A¤W¦~¦P´ÁÁ«·l5.15»õ¤¸¡A¨º¬O¬ü°êµ|°È§ï²³æ¤@¦¸ªº13.2»õ¤¸§Q¯q¼vÅT¡C
°£¥h³æ¤@¦¸¶µ¥Ø¡AValeant¨CªÑ¬Õ§Q98¥P¡A²¤¤ñ¤ÀªRû¹w´Áªº97¥P¦h¡C
¥¦ªº¦¬¤J¤U¶^10%¡A¨ì21.6»õ¤¸¡A²¤§C©ó¤ÀªRû¹w´úªº21.7»õ¤¸¡C